Prevention of type 2 diabetes: Lifestyle changes or pharmacological interventions?;Prevention du diabète de type 2: Style de vie ou médicaments?

Revue Medicale de Liege

Volumn 58, Issue 4, 2003, Pages 206-210

  Scheen, A J ^a   Letiexhe, M R ^b   Ernest, Ph ^a  

^a CHU SART TILMAN   (Belgium)

^b NONE

Author keywords

Acarbose; Diabetes mellitus; Diet; Exercise; Impaired glucose tolerance; Metformin; Orlistat; Prevention

Indexed keywords

ACARBOSE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; LACTONE;

CORONARY RISK; DIABETIC OBESITY; DIET; DISEASE ASSOCIATION; DRUG EFFICACY; EXERCISE; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; WORLD HEALTH ORGANIZATION; HEALTH BEHAVIOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HEALTH BEHAVIOR; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; LIFE STYLE;

EID: 0042932300     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. WHO Study Group. - Prevention of diabetes mellitus: report of WHO study group. WHO Tech Rep Ser, 1994, 844, 1-100.
2. Scheen AJ. - L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liege, 1999, 54, 87-94.
3. Scheen AJ, Paquot N, Jandrain B. - Comment j'explore ... le risque d'un patient d'évoluer vers un diabète de type 2. Rev Med Liège, 2002, 57, 113-115.
4. Donelly R, Garber A (Eds). - Progression of type 2 diabetes - inevitable or preventable ? Diab Obes Metab, 2001, 3 (Suppl 1), S1-S43.
5. Leahy JL. - The 2000s - decade of prevention. Curr Opin Endocrinol Diab, 2002, 9, 127-129.
6. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. - The prevention or delay of type 2 diabetes. Diabetes Care, 2002, 25, 742-749.
7. Scheen AJ. - Prévention du diabète de type 2 chez le sujet avec excès pondéral et diminution de la tolérance au glucose: efficacité des mesures hygiéno-diététiques. Rev Med Liège, 2001, 56, 463-465.
8. Scheen AJ, Paquot N, Letiexhe MR, Jandrain BJ. Approches pharmacologiques de prévention du diabète de type 2. Med Hyg, 2002, 60, 1480-1484.
9. Hu FB, Manson JE, Stampfer MJ, et al. - Diet, lifestyle, and the risk of type 2 diabetes in women. N Engl J Med, 2001, 345, 790-797.
10. Eriksson KF, Lindgarde F. - Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmö feasibility study. Diabetologia, 1991, 34, 891-898.
11. Pan XR, Li GW, Hu YH, et al. - Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Quing IGT and Diabetes Study. Diabetes Care, 1997, 20, 537-544.
12. Tuomilehto J, Lindström J, Ericksson JG, et al for the Finnish Diabetes Prevention Study Group. - Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med, 2001, 344, 1343-1350.
13. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
14. Scheen AJ. - Prévention pharmacologique de la progression de la diminution de la tolérance au glucose vers le diabète de type 2: effets favorables de la metformine et de l'acarbose. Rev Med Liège, 2001, 56, 727-730.
15. Chiasson J-L, Josse RG, Gomis R, et al for the STOP-NIDDM Trial Research Group. - Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 2002, 359, 2072-2077.
16. Scheen AJ. - Prevention of type 2 diabetes with α-glucosidase inhibitors. Drugs, 2003, in press.
17. Scheen AJ, Ernest Ph. - Antiobesity treatment in type 2 diabetes: results of clinical trials with orlistat and sibutramine. Diab Metab, 2002, 28, 437-445.
18. Heymsfield SB, Segal KR, Hauptman J, et al. - Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med, 2000, 160, 1321-1326.
19. Keating GM, Jarvis B. - Orlistat. In the prevention and treatment of type 2 diabetes mellitus. Drugs, 2001, 61, 2107-2119.
20. Scheen AJ. - Prévention du diabète de type 2 chez le sujet obèse: premiers résultats avec l'orlistat dans l'étude XENDOS. Rev Med Liège, 2002, 57, 617-621.
21. Scheen AJ. - Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liège, 2002, 57, 449-452.
22. Yusuf S, Gerstein H, Hoogwerf B, et al. - Ramipril and the development of diabetes. JAMA, 2001, 286, 1882-1885.
23. Hansson L, Lindholm LH, Niskanen L, et al. - Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 1999, 353, 611-616.
24. Yusuf S, Gerstein H, Hoogwerf B, et al. - Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 2000, 342, 145-153.
25. Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group. - Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
26. Hansson L, Lithell H, Skoog I, et al. - Study on Cognition and Prognosis in the Elderly (SCOPE). Blood Press, 1999, 8, 177-183.
27. Scheen AJ, Krzesinski J-M. - Quel antihypertenseur en première intention? Résultats de l'étude ALLHAT. Rev Med Liège, 2003, 58, 47-52.
28. Scheen AJ, Paquot N, Letiexhe MR, Lefèbvre PJ. - Les thiazolidinediones. In: Journées de Diabétologie de l'Hôtel-Dieu. Flammarion, Médecine-Sciences, Paris, 1999, 213-229.
29. Buchanan TA, Xiang AH, Peters RK, et al. - Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 2002, 51, 2796-2803.